ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Cesca Therapeutics — Presentation to Dawson James Securities (May 2017)

22 slides from ThermoGenesis's conference presentation, May 11, 2017

  1. Slide 1: Clinical Excellence in Stem Cell Applications

    SK A Boyalife Company Clinical Excellefigiadn Stem Cell Applications Presentation to Dawson James Securities May 11, 2017 Chris Xu, Ph.D., Chairman & Interim CEO Vivian Liu, COO

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current views and assumpt

  3. Slide 3: Who We Are

    Who We Are > Cesca is a leading regenerative medicine company that develops, commercializes and markets automated technologies for cell-based therapeutics. = Device division — ThermoGenesis — develops and markets a full suite of solutions for automated clinical biobanking, point-of- care application

  4. Slide 4: Financial Snapshot

    nO 50 2050 20 50 28 22 22 28 oe oe oe oe 2 2 ee ee ees Financial Snapshot * Nasdaq: ¢ Recent close: ¢ Shares out: ¢ Fully diluted: ¢ Market cap: ¢ 52 Week High/Low: ¢ TTM Revenue: * Cash: ¢ Largest Shareholder: 4| NASDAQ: KOOL KOOL $3.23* 9.9 million 14.4 million $31.7 million $7.39/$1.85 $14 millio

  5. Slide 5: Cell-Based Therapeutics — Next Pillar of Medicine?

    Cell-Based Therapeutics — Next Pillar of Medicine? Cell-based therapeutics — next pillar of medicine M.A. Fischbach, JA. Bluestone and WA. Lim —— Science Translational Mediicine, Vol. 5, Issue 179, pp.179 Two decades ago, the pharmaceutical industry—long dominated by small-molecule drugs—was revolut

  6. Slide 6: Cesca - Leading Provider of Automation for Cell-Based Therapeutics

    Cesca - Leading Provider of Automation for Cell-Based Therapeutics &: ESCA Clinical Development (USA) A Boyalife Company [ ] , % eS thermogenesis’ Hecate Tou petent RC" (USA) Clinical Development (India) 6 | NASDAQ: KOOL

  7. Slide 7: Global Clients in Stem Cell Industry

    Global Clients in Stem Point-of-Care/Lab-based Cell Industry (partial list) cGMP 4New York Closed Systems Blood Center Scalable ° - cordlife ‘one chance, one choice TEXAS CRYOLIFE THE UNIVERSITY OF TEXAS HealthBaby MD Anderson 2 i hina CordBloed Corporation Ganeer Center 2 , Duke Or aemn mn mr ame r

  8. Slide 8: Cesca's Automated Solutions for Cell-based Therapeutics

    DSO N50 Ne 50 2 52 22 2 oe ee ee ne Se ne sees Cesca’s Automated Solutions for Cell-based Therapeutics * Clinical BioBanking AXP® + BioArchive® provide automated isolation, collection and storage of cord blood stem cell concentrates * Point-of-Care Solutions for Cell-Based Therapeutics MxXP™, allows

  9. Slide 9: Strategic Focus

    Strategic Focus (1) Advancing proprietary technologies for automated Point-of-Care (PoC) autologous cell processing 9| NASDAQ: KOOL

  10. Slide 10: AutoXpress — Fast Growing Need for Autologous Cellular Processing at Point-of-Care

    AutoXpress™ — Fast Growing Need for Autologous Cellular Processing at Point-of-Care Clinic Setting * MXP™ The AutoXpressTM Device delivers an automated, rapid, “smart- vision” based cell enrichment and ensures consistency and reliability at Point-of-Care setting Various applications for vascular dis

  11. Slide 11: Point-of-Care for Autologous Cell Applications

    Point-of-Care for Autologous Cell Applications rrowXpres: ¢ Fast Point-of-Care device for cellular processing in the Operating Room * Peripheral blood or bone marrow * Minimally manipulated * High cell dose accuracy and potency ° Safe and Fast + Autologous bone marrow derived stem cells * Single 60

  12. Slide 12: Strategic Focus (II)

    Strategic Focus (Il) (2) Developing clinical applications around proprietary Point-of-Care (PoC) platform 12| NASDAQ: KOOL

  13. Slide 13: Strong Growth in Autologous Cell Applications

    Strong Growth in Autologous Cell Applications —+ Autologous Related Donor Unrelated Donor g = a a 2 £ re '83 '84 '85 '86 '87 '88 '89 '90 '91 ‘92°93 '94'95'96 '97'98 99'00'01 02'03'04''05 '06 '07'08'09 10 Source: CIBMTR 13 | NASDAQ: KOC

  14. Slide 14: Critical Limb Ischemia is the Most Severe Form of Peripheral Artery Disease

    di 14 | NASDAQ: KOOL * Critical Limb Ischemia (CLI) is the Most Severe Form of Peripheral Artery Disease ~ 1M Incidences in the U.S. Fueled by the Epidemic of Diabetes and the Aging Population Results in “70,000 Major Amputations and 134,000 Minor Amputations per annum in the U.S. Dismal Patient Out

  15. Slide 15: No Adverse Events Related to Treatment

    No Adverse Events Related to Treatment Major Amputation-Free Rate Post- Therapy of 82.4% in “No-Option” Patient Cohort Verified Revascularization, with Improvements in: Collateral Vessel Numbers & Size Ankle Brachial Index (ABI) Transcutaneous Oxygen Pressure (TcPO2) Reduction in Pain Claudication P

  16. Slide 16: US FDA Approved Phase III - CLI Clinical Trial

    nO 50 2050 20 50 28 22 22 28 oe oe oe oe 2 2 ee ee ees US FDA Approved Phase III - CLI Clinical Trial Clinical Trial Design Endpoints Superiority Study — Treatment vs. Sham Primary Endpoint: + Randomized (1:1), Double Blinded Study + The difference in AFS measured over 12 + Rutherford 4&5 months bet

  17. Slide 17: Pipeline in Development

    Pipeline in Development AMI 40 Phase 1b IRB Approved Stroke 415 Phase 1a Under Regulatory Review Cardiovascular ay Phase 1b Completed (Intra- CLI 13 Muscular) Phase 1 Completed (Intra-Arterial) Non Healing Ulcers 10 Pilot OA 50 Pilot Completed A . 30 Pilot Completed Non U: Onineaaclte behest 17 Phas

  18. Slide 18: Building a Pipeline Around Proprietary Platform

    Building a Pipeline Around Proprietary Platform Indication Pre-Clinical/Pilot PI/ib Pu Pll Platform Market Vascular AMI Single Patient SurgWerks | $700M cu SurgWerks $28 Ischemic Stroke | éE Non-Healing Ulcer Eo $800M Orthopedic SIS Spinal Fusion surgWerks | $800M Osteoarthritis surgWerks | $5B Non-

  19. Slide 19: Strategic Focus (III)

    Strategic Focus (Ill) (3) Developing automations for immuno-oncology applications, i.e. CAR-T 19 | NASDAQ: KOOL

  20. Slide 20: Immuno-Oncology Applications

    Immuno-Oncology Applications CXP™ + BioArchive® = automated manufacturing, expansion and storage of cellular therapies for immuno-oncology, including various T-cell and nature killer (NK) cell based therapies 20 | NASDAQ: KOOL pes

  21. Slide 21: Milestones for Next Months

    Milestones for Next 12 Months ¢ Expand medical device product pipeline ¢ Transform clinical program by building a robust clinical pipeline based on proprietary AutoExpress™ platform ¢ Secure one or more strategic partnerships for clinical co-development fCESCA 21| NASDAQ: KOOL aN

  22. Slide 22: Thank You!

    Thank You ! Company Contact: Vivian Liu [email protected] 916-858-5185 Investor Contact: Paula Schwartz Paula Schwartz <[email protected]> RX Communications 917-322-2216

Cesca Therapeutics — Presentation to Dawson James Securities (May 2017) on 6ix